<DOC>
	<DOCNO>NCT01577095</DOCNO>
	<brief_summary>Aims : To evaluate efficacy rosiglitazone ( TZD ) electroacupuncture ( EA ) combine therapy patient type 2 diabetes mellitus ( T2DM ) . A randomized single-blind placebo control clinical trial use . Methods : A total 31 newly diagnostic type 2 diabetic patient , fulfil eligibility criterion recruit receive various allocated intervention . They randomly assign two group , control group ( TZD , N=15 ) experimental group ( TZD + EA , N=16 ) . Changes plasma free fatty acid ( FFA ) , glucose insulin level together homeostasis model assessment ( HOMA ) indices statistically assess treatment . Hypoglycemic activity ( % ) also compare two group . Expecting Results : This study compare hypoglycemic activity ability improve insulin resistance TZD TZD+EA group . Also , lower effect plasma FFA concentration investigate .</brief_summary>
	<brief_title>Evaluating Effects Electroacupuncture Rosiglitazone Combined Therapy</brief_title>
	<detailed_description>This study compare effect combine therapy ( EA+TZD ) drug ( TZD ) patient type 2 DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>include native Taiwanese patient , age 20 65 year diagnose type 2 diabetes mellitus within 5 year keep antihyperglycemic agent control diabetes period study compatible diagnostic criterion diabetes mellitus accord American Diabetes Association individual nephrotic syndrome ( urine protein 3.5 g/day ) edema renal failure ( serum creatinine 115 Î¼mol/L ) individual diagnose heart failure ( NYHA Fc III~IV ) pacemaker implantation individual abnormal liver function ( GOT GPT level 2 fold normal range ) diagnosis liver cirrhosis individual higher HbA1C level ( HbA1C 9 % ) pregnant woman individual receive class drug thiazolidinediones already individual receive insulin therapy already individual receive therapy period study individual suffer homeostasis disorder systemic disease individual comply treatment study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>electroacupuncture</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>plasma glucose</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>free fatty acid</keyword>
</DOC>